Biotech startup ecosystem
Europe's biotech ecosystem benefits from world-class research universities, strong IP frameworks, and growing specialist VC funds. The UK, Switzerland, and the Nordics are particularly strong in drug discovery, diagnostics, and synthetic biology. We track 106 organisations in this sector across 6+ countries.
Showing 101–106 of 106Biotech
Countries in this sector
Sectors alongside this one
Biotech results
Tech Open Air (TOA) 2026
Large interdisciplinary tech festival at Funkhaus Berlin combining AI, synthetic biology, Web3, and health tech with music, art, and science programming. Includes startup visibility opportunities and a headline startup pitch competition.
Turbine
Turbine is a Budapest-based biotech company using AI-powered simulated cell technology to accelerate drug discovery and identify novel cancer treatment combinations. The platform creates virtual cell models that simulate how cancer cells respond to different drug interventions, helping pharmaceutical companies identify promising candidates faster and with fewer costly wet-lab experiments. Turbine has partnered with major pharma companies and raised significant funding to expand its simulated biology platform. The company is a standout example of deep-tech life sciences innovation emerging from Hungary and one of the most technically ambitious AI-for-drug-discovery startups in Central Europe.
UtrechtInc
Founded 2009. University-affiliated incubator supporting ICT and biotech startups with a 4-month validation program, follow-on acceleration, labs access, and investor network. Supported 200+ startups including SnappCar. Scope: Regional (Utrecht).
Voima Ventures
Voima Ventures was founded in 2019 in Helsinki by Inka Mero, a serial entrepreneur and investor, and specialises exclusively in science-based deep tech spin-outs from universities and research institutions across the Nordics and Baltics. The firm raised its third fund of €90 million in 2023, bringing total assets above €100 million, and invests €200,000–€3 million at the earliest stages in biotech, quantum, AI, energy, climate, and life sciences. Over 70% of its 51 portfolio companies originate directly from academic labs, including Solar Foods. Voima is one of the few female-founded and female-led VC funds in the Nordics.
World ADC London 2026
Flagship antibody-drug conjugate summit in London bringing together biopharma leaders, biotech investors, and clinical researchers. Covers next-generation ADC design, payload innovation, and clinical trial data from leading oncology programs. Valuable for biotech startups developing targeted therapies and seeking licensing or co-development partnerships.
World ADC London 2027
World ADC London returns 8-11 March 2027 as Europe's longest-standing forum dedicated to antibody-drug conjugates (ADCs) and bioconjugates. Previous editions united 700+ senior European decision-makers across biopharma, clinicians, service providers, investors and regulators. It is organised by Hanson Wade Conferences.
